Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - Nov 14, 2024 - "UPCOMING EXPECTED EVENTS AND MILESTONES:...(i) Complete ReSPECT-LM Phase 1 single dose administration trial and determine the maximum tolerated and recommended Phase 2 doses by year-end; (ii) Initiate ReSPECT-LM Phase 1 multiple dose administration trial in 2025; (iii) Complete ReSPECT-GBM Phase 2 enrollment by 2025; (iv) Obtain IND approval for a Phase 1/2 trial of Rhenium (186Re) Obisbemeda for pediatric ependymoma and high-grade glioma."
IND • Trial status • Ependymoma • Glioblastoma • Glioma
|